Details of the Directors and Senior Management

Board of Directors
Senior Management

Board of Directors

Summarized biographies of the Directors and details of their roles, including the principal activities performed by the Directors outside the Company, are set out below.

Stark Thompson, PhD - Non-executive Chairman

Dr. Thompson joined the DuPont Company in 1967 and assumed business management responsibility for the global Clinical Systems Division, a position he held until he left DuPont in 1988. From 1988 until 2000, Dr. Thompson was appointed President, CEO and board member of Life Technologies, Inc. (LTI; NASDAQ: LTEK) ("LTI"). Between 1988 and 2000, LTI grew to become the leading developer, manufacturer and supplier, worldwide, of products and services for life science researchers and companies using biotechnology to produce therapeutics. Dr. Thompson retired from LTI after its takeover in November 2000.

Dr. Thompson has served on the board of directors of ATTO Biosciences; was board chair of Gene Logic, Inc. and was a board member of Ore Pharmaceutical Holdings, Inc. (NASDAQ: ORXE). He was on the board of Luminex Corporation (NASDAQ: LMNX) from 2005 to June 2009 and was a member of the board of Naurex, Inc. Dr. Thompson received his BS degree from Muskingum University, and his MSc and PhD in Physiological Chemistry from Ohio State.
Doug Doerfler - President and Chief Executive Officer

Mr. Doerfler has over 30 years' experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Prior to joining MaxCyte, Mr. Doerfler held senior corporate development and operating responsibilities for a privately owned biotechnology holding company. He was President, Chief Executive Officer and a director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with LTI that included leading its global businesses, mergers and acquisitions and its IPO. Mr. Doerfler plays an active role as an advocate for the life sciences industry. He is Chair of the Tech Council of Maryland and serves on the Executive Committees of the Alliance for Regenerative Medicine and the Biotechnology Industry Organization ("BIO"), and Co-Chairs BIO's Capital Formation Committee. Mr. Doerfler received his B.S. in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.
Ron Holtz – Chief Financial Officer

Mr. Holtz serves as MaxCyte's Chief Financial Officer, having joined the Company in 2005. During his career, Mr. Holtz has been Chief Financial Officer of both public and private companies and has raised more than $100m in debt and equity capital. Prior to joining MaxCyte, Mr. Holtz was Chief Financial Officer of B2eMarkets, a privately held software solutions company targeting Global 1000 companies. Mr. Holtz also served as Vice President and Chief Financial Officer of RWD Technologies ("RWD"), a leading information technology and performance improvement consulting firm, where he led RWD's initial public offering and was responsible for finance, acquisitions, business management and analyst/investor relations. Prior to this, Mr. Holtz was a manager in Ernst & Young LLP's Financial Advisory Services Group. He earned a Master's of Business Administration in finance from the University of Maryland, a Bachelor's of Science degree in mathematics from the University of Wisconsin and is a Certified Public Accountant.
Will Brooke – Non-executive Director

Mr. Brooke is Executive Vice President and a director of Harbert Management Corporation ("HMC"), which he co-founded in 1993. With approximately $4 billion under management, HMC sponsors and co-invests in alternative asset strategies worldwide. Mr. Brooke organized and led one of HMC's investment strategies, Harbert Venture Partners, for over a decade when the firm raised three venture capital funds and he lead numerous healthcare and biotech investments for the funds. Mr. Brooke has been advising and investing in early stage and growth companies for more than 20 years, and served on the boards of numerous pharmaceuticals and medical equipment companies, including nContact Corporation, Aldagen Corporation, Innovative Biosensors, Inc., NovaMin Technologies, Inc., Optimal Readings Services Group, Inc., Atherotech, Inc. and Emageon Corporation. Mr. Brooke has also served as HMC's General Counsel, its Chief Operating Officer, and as chairman of its Real Estate Services subsidiary. Prior to joining HMC, Mr. Brooke practiced law for a decade, during which he organized and served as Managing Partner of a commercial law firm. Mr. Brooke holds degrees in law (J.D.) and Business Management (B.S.), each from the University of Alabama.
Stan Erck – Non-executive Director

Mr. Erck, President and CEO, and director of Novavax Corporation, applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept, Integrated Genetics, and Iomai) to shepherd the development and commercialization of Novavax Technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through to IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.
Art Mandell – Non-executive Director

Mr. Mandell is a senior executive in the health care industry with over 30 years of experience running companies, executing large corporate and business development deals in both the pharmaceutical and biotechnology sectors, and developing and commercializing a number of products. Mr. Mandell served as President and Chief Operating Officer of Prestwick Pharmaceuticals, Inc. ("Prestwick"). Prior to Prestwick, Mr. Mandell was President, Chief Executive Officer, and a director of Cellective Therapeutics, Inc. ("Cellective"), a monoclonal antibody company developing therapeutic products for autoimmune and oncology diseases. Under his leadership, Cellective was acquired by Astra Zeneca/MedImmune Inc. Before Cellective, Mr. Mandell served as President, Chief Executive Officer, and director of Stemron Corporation, a therapeutic stem cell start up company in Gaithersburg, Maryland and prior to joining Stemron Corporation, he served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. ("HGS"), a biotechnology leader in Gaithersburg, Maryland. Mr. Mandell began his healthcare career at Syntex Pharmaceutical Corporation, where he had profit and loss responsibility for all subsidiaries in the Pacific Rim, Canada and Mexico.
John Johnston – Proposed Non-executive Director

Mr. Johnston is currently Non-executive director of Action Hotels plc, Flowgroup plc and Midatech Pharma plc, Non-executive chairman of Constellation Healthcare Technologies Inc., and prior to this was managing director of Institutional Sales at Nomura Code. He was previously director of Sales and Trading at Seymour Pierce from 2008 to 2011. In 2003, Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. From 1992 to 1997, Mr. Johnston was Head of Small Companies at Scottish Amicable, before spending a year at Ivory and Sime, again as Head of Small Companies from 1997 to 1998. He joined Legg Mason Investors for three years as director of Small Companies Technology and Venture Capital Trusts, from 2000 to 2003, having previously spent two years as Head of Small Companies with Murray Johnstone. Mr. Johnston began his investment career at the Royal Bank of Scotland in 1981, working in the Trustee and Investment department, before moving to General Accident in 1985, holding the position of Head of Retail Funds before his move to Scottish Amicable.
Back to Top

Senior Management

Short biographies of the Company's senior management and details of their roles are set out below:

Madhusudan Viswanath Peshwa, PhD, Chief Scientific Officer, Executive Vice President, Cellular Therapies

Dr. Peshwa currently serves as Chief Scientific Officer at MaxCyte, having joined the Company in 2005. He was Executive Vice President for Research and Development at NewNeural, a start-up stem cell therapy company. Previously, Dr. Peshwa served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where he was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and in cGMP systems for the development of engineered cell and tissue products and for biopharmaceuticals production. Dr. Peshwa obtained his PhD in chemical engineering from the University of Minnesota and his BTech in chemical engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.
Thomas Michael Ross, Executive Vice President, Global Sales

Mr. Ross serves as MaxCyte's Executive Vice President of Global Sales, having joined the Company in 2014. Mr. Ross has extensive experience in all elements of commercial operations and has over 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. Mr. Ross also served as Chief Commercial Officer at Predictive BioScience and Vice President of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, Mr. Ross held several senior leadership roles in Manufacturing Operations at LTI and Cambrex.
Back to Top


Frank H. Valone, M.D.
FibroGen. Inc.

Dr. Valone is Chief Medical Officer of FibroGen. Inc. and brings more than 20 years of biotechnology industry experience in the leadership of clinical and preclinical development, medical and regulatory affairs, and quality assurance and control. Dr. Valone was most recently Senior Vice President of Medical Affairs at Bayhill Therapeutics where he was responsible for clinical, regulatory, quality and nonclinical toxicology/safety aspects related to the development of Bayhill's investigational therapies. Prior to Bayhill, Dr. Valone was Executive Vice President, Clinical Development and Regulatory Affairs of Titan Pharmaceuticals, Inc., and prior to that, he was Senior Vice President, Medical and Regulatory Affairs at Dendreon Corporation where he oversaw the advancement of the company's lead product for prostate cancer, Provenge® (sipuleucel-T), from phase 1 into phase 3 clinical testing.
Kim Lyerly, M.D., FACS
Duke University School of Medicine

Dr. Lyerly serves as a Professor of Surgery, Associate Professor in the Department of Pathology, and Assistant Professor in the Department of Immunology at Duke University School of Medicine. Dr. Lyerly has been Director of the Duke Comprehensive Cancer Center since 2003. He serves as the George Barth Geller Professor for Research in Cancer and is an experienced surgical oncologist. Dr. Lyerly serves as Co-Leader of the Breast and Ovarian Oncology Research Program at Duke and principal investigator of the Duke Specialized Program in Research Excellence (SPORE) grant in breast cancer. Dr. Lyerly also holds faculty appointments in Duke's pathology and immunology departments. He serves as a member of the Scientific Advisory Boards for VentiRx Pharmaceuticals, Inc., Alphavax Inc., Amphora Discovery Corporation, Immunotope, Inc., Targeted Molecular Diagnostics LLC., and the Susan G. Komen for the Cure. He serves on the Editorial Boards of several peer-reviewed journals, including Cancer Investigation, Clinical Cancer Research, and Cancer Gene Therapy. Dr. Lyerly serves as a consultant and advisory board member to the National Cancer Institute, WebMD, and various biotechnology and pharmaceutical companies. He co-directs the NCI-sponsored workshop of cancer clinical trials and is the scientific chair of the Southwest Oncology Group Molecular Therapeutics Committee. He is on the editorial board of several publications, including Surgery, Annals of Surgery, and Clinical Cancer Research. He was trained in Surgery at Duke University Medical Center from 1984 to 1985 and 1987 to 1990 and in Research at Duke University Medical Center from 1985 to 1987. Dr. Lyerly received his M.D. from the University of California, Los Angeles.
Richard Stead, M.D.
BioPharma Consulting Services, LLC

Dr. Richard Stead has more than 20 years of experience in the biotechnology and pharmaceutical industry directing clinical trials, in- and out- licensing efforts, as well as preclinical research and development at Amgen and Immunex. Since 2002, he has worked as an independent consultant to biotechnology and pharmaceutical companies as well as investors in several therapeutic areas. He focuses on clinical and regulatory strategy for therapeutic product development as well as operational issues in executing clinical development programs. In 1988, Dr. Stead was recruited to Amgen as its first physician. He played significant roles in the clinical development, FDA approval, and commercialization of Amgen's first two products, Epogen® and Neupogen®. In 1999, he joined Immunex as Vice President of Clinical Research and Development with responsibilities for both pipeline and marketed products for Oncology and Neurology. He negotiated the approval and post-marketing commitments for the approval of Novantrone® in multiple sclerosis with the FDA. Dr. Stead graduated from the University of Wisconsin and Stanford University School of Medicine. He completed his medical training at the Brigham and Women's Hospital and Harvard Medical School and a second post-doctoral fellowship at the National Cancer Institute.
Back to Top